RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating
RBC Capital has increased its price target for Mirum Pharmaceuticals (MIRM) to $148 from $142, while maintaining an Outperform rating on the stock. This adjustment reflects continued analyst confidence in the biopharmaceutical company, which focuses on treatments for rare liver diseases. The company's key medications include LIVMARLI, Cholbam, and Chenodal, with a promising product candidate, volixibat, in development.
Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM)
Eric Bjerkholt has reported the sale of 5,000 shares of Mirum Pharmaceuticals (MIRM) common stock on June 8, 2026, with a reported value of $469,073.00. This transaction was disclosed via a Form 144 filing, which is a routine notice for proposed sales of restricted securities. The shares were restricted stock dated September 11, 2024.
Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM)
Christopher Peetz has filed a Form 144 indicating a proposed sale of 20,000 shares of Mirum Pharmaceuticals (NASDAQ: MIRM) common stock, which will be executed via a stock option exercise on July 6, 2026. The filing also reports a previous sale of 30,000 shares on June 1, 2026. This notice is a regulatory requirement for planned sales of restricted or controlled securities, ensuring transparency in the market.
FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals has received FDA priority review for zilurgisertib following positive Phase II results for fibrodysplasia ossificans progressiva, with a decision expected in late September 2026. This accelerated review and promising data could expand Mirum's rare disease portfolio and reshape its investment narrative. Despite current net losses, the company is investing heavily, projecting significant revenue and earnings growth by 2029.
Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM
This article provides financial information for Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) on TradingView. It focuses on the company's enterprise value to EBIT forward metric. The content highlights the stock's market data and available financial tools on the platform.
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125
J.P. Morgan has reiterated its Buy rating for Mirum Pharmaceuticals (MIRM.US) and increased its price target to $125. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.
Mirum Pharmaceuticals SVP sells $326,520 in common stock
Jolanda Howe, Senior Vice President at Mirum Pharmaceuticals, sold 2,721 shares of the company's common stock for $326,520, with shares trading at $120.0 each. This sale occurred while the stock was near its 52-week high after a significant 156% gain over the past year, and was executed according to a Rule 10b5-1 trading plan. The article also mentions recent positive analyst ratings and strategic company developments for Mirum Pharmaceuticals.
MIRM - Mirum Pharmaceuticals Inc Latest SEC Filings
This article provides the latest SEC filing information for Mirum Pharmaceuticals Inc. (MIRM), offering a comprehensive overview of its financial performance, key valuation metrics, and stock market statistics. It details various financial ratios, insider and institutional ownership, profitability, and price performance over different periods.
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM)
Jolanda Howe, Senior Vice President, Global Controller at Mirum Pharmaceuticals Inc, sold 2,721 shares of the company on July 1, 2026, reducing her holdings to 3,114 shares. This transaction is part of a pattern of 39 insider sells against only 1 insider buy for MIRM over the last year. The stock is currently trading at $120, which is significantly overvalued according to its GF Value of $82.40.
Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan
Mirum Pharmaceuticals' SVP and global controller, Jolanda Howe, sold 2,721 shares of common stock at $120.00 per share in an open-market transaction. This sale, totaling $326,520, was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following the transaction, Howe directly holds 3,114 shares of Mirum Pharmaceuticals.
Mirum Pharmaceuticals (MIRM) Rallies On Trial News As Its Valuation Story Gets Harder To Ignore
Mirum Pharmaceuticals (MIRM) shares rallied 5.5% after positive phase II data and an FDA priority review for zilurgisertib, impacting its market value which now stands at US$7.3 billion. The stock has seen a strong uplift with a 25.05% return in 30 days and 54.30% year-to-date, prompting investors to scrutinize its current valuation, which, at $120.46, is still below the average analyst target of $144.15 per share. However, the company faces risks including its reliance on LIVMARLI and potential trial/regulatory setbacks.
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD
Mirum Pharmaceuticals' stock reached an all-time high of $125.41, bringing its market capitalization to $7.6 billion, despite an InvestingPro analysis suggesting it might be overvalued. The company has seen a 147.06% increase over the last year and strong revenue growth of 50%. Recent developments include pricing $600 million in convertible senior notes, positive analyst coverage with high price targets, and the acquisition of zilurgisertib.
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com
Mirum Pharmaceuticals' stock reached an all-time high of $125.41, marking a 147.06% increase over the past year and bringing its market capitalization to $7.6 billion. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. The company has also recently announced pricing $600 million in convertible senior notes and received positive analyst coverage and price target increases from Wolfe Research, Citizens, and H.C. Wainwright.
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib
Mirum Pharmaceuticals recently reported positive phase II results for zilurgisertib in fibrodysplasia ossificans progressiva (FOP) and received FDA priority review. This development could reshape the investment narrative for Mirum, moving it beyond its reliance on Livmarli and strengthening its rare disease portfolio with multiple late-stage assets. While offering significant new opportunities, this also amplifies financial risk if these expensive programs underperform.
Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com
This article from Investing.com reports the filing of Form 144 for MIRUM PHARMACEUTICALS on July 1st. It provides the headline and mentions the stock symbol MIRM, along with a slight percentage increase. The article is very short and largely surrounded by extensive financial market data, news links, and navigational elements typical of a financial news portal.
2,721 performance shares proposed; Jolanda Howe sold 2,594 (MIRM)
A Form 144 filing by Morgan Stanley Smith Barney LLC Executive Financial Services discloses a proposed resale of 2,721 performance shares of Mirum Pharmaceuticals, Inc. (MIRM) dated March 15, 2026. The filing also reports that Jolanda Marie Howe previously sold 2,594 common shares for $264,458.30 on June 17, 2026. These transactions are routine compliance disclosures detailing intended and completed sales of securities.
Mirum Pharmaceuticals Stock Surges 25%, With A 9-Day Winning Spree
Mirum Pharmaceuticals (MIRM) recently experienced a 9-day winning streak, with its stock surging 25% and its market cap increasing by about $1.4 billion to $7.3 billion. While the company demonstrates strong operating performance, its current valuation is considered very high, making the stock appear relatively expensive. The article emphasizes the importance of predictive signals for identifying opportunities before they become public knowledge, rather than reacting to news after it has already impacted the market.
Price to book forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM
This article provides financial information for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), focusing on its forward price-to-book ratio. It appears to be a stub or an entry from a financial data platform, indicating the company's financials, news, community, technicals, and forecasts are available. The content primarily lists navigation and site information rather than detailed financial analysis.
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw a 5.5% share price jump, potentially driven by positive Phase II data for zilurgisertib in FOP and its subsequent FDA priority review. Despite this recent strength, the company faces a projected quarterly loss and a 9.5% downward revision in consensus EPS estimates, prompting a "Hold" rating from Zacks. Investors are advised to monitor MIRM closely for future performance amidst these conflicting indicators.
Enterprise value to EBITDA forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM
The article focuses on the enterprise value to EBITDA forward for Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM). It is a financial data page from TradingView, presenting a specific financial metric for the company. The content primarily lists navigation and platform features, rather than detailed financial analysis.
Mirum Pharmaceuticals (MIRM) Is Up 15.5% After Positive FOP Phase 2 Data for Zilurgisertib
Mirum Pharmaceuticals' stock rose 15.5% following positive Phase 2 data for its oral ALK2 inhibitor, zilurgisertib, in treating fibrodysplasia ossificans progressiva (FOP). This data, combined with FDA Priority Review and a September 26, 2026 PDUFA date, positions zilurgisertib as a potential diversification for Mirum's rare disease portfolio. While this offers a strong near-term regulatory catalyst, the company still faces high spending and relies heavily on existing bile acid drugs for current revenue.
Enterprise value to revenue forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM
The article focuses on the "Enterprise value to revenue forward" metric for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM). It appears to be a financial data point displayed on the TradingView platform. The content primarily shows the navigation and footer of the TradingView website, with the core article content being minimal and largely acting as a title for a data display.
Understanding Momentum Shifts in (MIRM)
This article analyzes Mirum Pharmaceuticals Inc. (MIRM) using AI models, identifying strong sentiment across all horizons supporting an overweight bias. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also provides multi-timeframe signal analysis with specific support and resistance levels.
MIRM Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Mirum Pharmaceuticals, Inc. (MIRM) stock, based on analyst opinions. It includes current stock performance, historical highs and lows, volatility, market capitalization, financial results, upcoming earnings dates, and dividend information. The consensus among analysts indicates a "strong buy" rating for the stock.
Mirum Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRM)
This article provides an overview of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), detailing its financial actuals and analyst estimates. It includes current stock price, historical performance, analyst price targets, and key financial metrics like market capitalization, revenue, net income, and EBITDA. The company does not pay dividends and has 372 employees as of June 26, 2026.
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?
Mirum Pharmaceuticals (MIRM) is being recognized as a promising rare disease growth story, with Citizens reiterating a positive stance and increasing its price objective to $146 due to the potential of its zilurgisertib program for fibrodysplasia ossificans progressiva (FOP). The company also issued inducement awards to new employees. Mirum focuses on developing therapies for rare liver and metabolic disorders.
08D Forecast — Price Target — Prediction for 2027
This article provides a forecast and analysis for Mirum Pharmaceuticals, Inc. (08D) stock, including analyst price targets, historical performance, and key financial metrics. It highlights the current stock price, recent changes, analyst ratings, and details around earnings, revenue, market capitalization, and volatility.
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?
Mirum Pharmaceuticals (MIRM) is being recognized as a potential rare disease growth story following new data for its zilurgisertib program in fibrodysplasia ossificans progressiva (FOP). Citizens reiterated a positive stance on MIRM and increased its price target to $146, citing encouraging clinical activity despite the Phase 2b study not meeting its primary goal. The company also recently granted inducement awards, including stock options and RSUs, to new employees.
Mirum Pharmaceuticals stock hits all-time high at 114.99 USD
Mirum Pharmaceuticals (MIRM) stock has reached an all-time high of $114.99, marking a 128.41% increase over the past year and a 40.6% year-to-date return. The biopharmaceutical company, now valued at $6.98 billion, has also reported 50% revenue growth in the last twelve months as of Q1 2026. This surge is supported by recent strategic moves including a $600 million convertible senior notes offering and positive analyst ratings from Wolfe Research, Citizens, and H.C. Wainwright.
Mirum Pharmaceuticals (MIRM) Stock Could Be 26% Undervalued After Zilurgisertib Phase 2 Results
Mirum Pharmaceuticals' (MIRM) stock is considered 26% undervalued, trading at $107.13 against a narrative fair value of $144.15, following positive Phase 2 data for zilurgisertib and FDA Priority Review for its NDA. The company shows strong recent momentum with significant share price returns and multiple late-stage pipeline catalysts driving analyst optimism. Despite this, investors are urged to consider underlying risks such as reliance on LIVMARLI and potential competition.
Mirum Pharmaceuticals (MIRM) Stock Could Be 26% Undervalued After Zilurgisertib Phase 2 Results
Mirum Pharmaceuticals (MIRM) stock is currently trading at $107.13, yet analysis suggests it could be 26% undervalued with a narrative fair value of $144.15. The company recently reported positive Phase 2 data for zilurgisertib and has an FDA Priority Review for its New Drug Application, contributing to its strong recent stock performance. Despite its potential, Mirum relies heavily on LIVMARLI, and faces risks from competition and pricing pressures.
Values First Advisors, Inc.'s Mirum Pharmaceuticals Inc(MIRM) Holding History
Values First Advisors, Inc. holds 9,397 shares of Mirum Pharmaceuticals Inc (MIRM), valued at $868,060, making up 0.45% of their portfolio. The firm has a significant estimated gain of $1.46 million (91.80%) on their MIRM holdings, acquired through multiple purchases and sales since 2023Q1. The article provides a summary of their trading activity and recent news related to Mirum Pharmaceuticals.
Mirum Shareholders Approve Directors, Auditors and Compensation
Mirum Pharmaceuticals shareholders approved the election of three Class I directors, Lon Cardon, William Fairey, and Timothy Walbert, to its board. They also ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 and approved the executive compensation program for named officers on an advisory basis. TipRanks' AI Analyst, Spark, rates MIRM stock as Neutral due to weak financial quality despite strong commercial momentum and raised guidance.
Mirum (MIRM) SVP Jolanda Howe sells 2,594 shares under Rule 10b5-1 plan
Mirum Pharmaceuticals SVP Jolanda Howe sold 2,594 shares of Common Stock at $101.95 per share, totaling $264,458. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following the sale, Howe directly holds 5,835 shares in the company.
Mirum (MIRM) director Lon Cardon granted RSUs and options at $101 strike
Mirum Pharmaceuticals director Lon Cardon was granted 1,980 restricted stock units (RSUs) and 3,772 stock options with an exercise price of $101.00 per share. These new equity awards are part of his compensation and are set to vest on the first anniversary of the June 15, 2026 grant date, or by the company's 2027 annual stockholder meeting. This transaction was reported via a Form 4 filing and did not involve any open market purchases or sales of shares.
Mirum (MIRM) director Michael G. Grey awarded RSUs and $101 stock options
Mirum Pharmaceuticals director Michael G. Grey was granted 1,980 restricted stock units (RSUs) and 3,772 stock options with an exercise price of $101.00 per share on June 15, 2026. These awards are routine equity compensation, not open-market transactions, and are scheduled to vest on the first anniversary of the grant date or by the company's 2027 annual stockholder meeting. The options have an expiration date of June 14, 2036, reflecting a long-term incentive structure.
Mirum Pharmaceuticals (MIRM) Is Up 8.6% After FDA Grants Priority Review to Zilurgisertib NDA
Mirum Pharmaceuticals' stock rose 8.6% after the FDA granted Priority Review to its New Drug Application for zilurgisertib, an oral ALK2 inhibitor. This drug showed positive results in the Phase 2 PROGRESS study for fibrodysplasia ossificans progressiva (FOP), a rare disease. The FDA's decision could significantly impact Mirum's valuation and long-term growth, broadening its rare-disease portfolio beyond Livmarli.
Mirum Pharmaceuticals (MIRM) stockholders back 2026 directors, auditor and pay package
Mirum Pharmaceuticals, Inc. (MIRM) stockholders approved the election of three Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm, and the advisory compensation of named executive officers at their 2026 Annual Meeting. The record date for voting was April 20, 2026, with over 60 million shares entitled to vote. All proposals received sufficient votes for approval.
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM)
Jolanda Howe, Senior Vice President, Global Controller at Mirum Pharmaceuticals Inc (MIRM), sold 2,594 shares of the company on June 17, 2026, reducing her holdings to 5,835 shares. This transaction is part of a pattern where insiders at Mirum Pharmaceuticals have conducted 38 sells and only 1 buy over the past year. The stock is currently trading at $101.95, which is considered modestly overvalued compared to its GF Value of $82.03.
Mirum Pharmaceuticals (MIRM) director receives RSUs and options grants
Mirum Pharmaceuticals director Saira Ramasastry was granted 1,980 restricted stock units and stock options for 3,772 shares, with an exercise price of $101 per share. Both awards vest on the first anniversary of the grant date (June 15, 2026) or by the company's 2027 annual stockholder meeting, with options expiring on June 14, 2036. This transaction represents compensation and not open-market trading activity.
Mirum Pharmaceuticals Inc (MIRM) Institutional Confidence
Mirum Pharmaceuticals Inc (MIRM) has an institutional shareholding score of 10.00, placing it first among 157 companies in the Pharmaceuticals industry. The institutional shareholding proportion is 111.53%, showing a slight decrease quarter over quarter. Key institutional shareholders include Frazier Life Sciences Management, Janus Henderson Investors, and BlackRock Institutional Trust Company.
Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Mirum Pharmaceuticals Inc's (MIRM) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page displays current stock metrics for MIRM, including its market cap and recent trading activity.
Mirum Pharmaceuticals Inc (MIRM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for Mirum Pharmaceuticals Inc (MIRM) as of April 6, covering FY2025 data. It details the company's revenue contribution from its key business segments: Livmarli and Bile Acid Medicines. The report indicates that Livmarli accounts for 69.06% of revenue, while Bile Acid Medicines contribute 30.94%.
Mirum Pharmaceuticals (MIRM) director granted options and 1,980 deferred stock units
Mirum Pharmaceuticals director Laura Brege received equity awards, including 1,980 deferred stock units and 3,772 stock options with an exercise price of $101.00 per share. Both awards vest on the first anniversary of the June 15, 2026 grant date, or in any case by the company's 2027 annual stockholder meeting. The deferred stock units will be settled in common stock upon a change in control or Brege's separation from service, and the options expire on June 14, 2036.
Mirum Pharmaceuticals (MIRM) director awarded RSUs and options in new equity grants
Mirum Pharmaceuticals director Timothy P. Walbert was granted 1,980 restricted stock units (RSUs) and 3,772 stock options with an exercise price of $101.00 per share. These equity awards, reported on June 15, 2026, will vest on the first anniversary of the grant date or by the company's 2027 annual stockholder meeting. After these transactions, Walbert directly holds 1,980 RSUs and 3,772 options, indicating compensation-related grants rather than open-market purchases.
Mirum Pharmaceuticals (MIRM) director receives deferred stock units and options grant
Mirum Pharmaceuticals director Patrick J. Heron has been granted 1,980 deferred stock units and 3,772 stock options as part of his compensation. The stock options have an exercise price of $101.00 per share. Both the deferred stock units and stock options will vest on the first anniversary of the grant date or by Mirum’s 2027 annual stockholder meeting, and the transactions do not involve open-market purchases or sales.
Director at Mirum (MIRM) awarded deferred stock units and options
Mirum Pharmaceuticals director William Fairey has been granted 1,980 deferred stock units and options for 3,772 shares of common stock with an exercise price of $101.00 per share. These awards are compensation and will vest on the first anniversary of the grant date, or by the company's 2027 annual stockholder meeting. The deferred stock units will be settled in common stock upon a change in control or Fairey's separation from service.
Avoiding Lag: Real-Time Signals in (MIRM) Movement
This article from Stock Traders Daily provides a real-time signal analysis for Mirum Pharmaceuticals Inc. (NASDAQ: MIRM), highlighting a near-term strong sentiment. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report also notes an exceptional risk-reward short setup targeting 11.4% downside.
Citizens raises Mirum Pharmaceuticals stock price target on drug deal
Citizens has increased its price target for Mirum Pharmaceuticals to $146 from $140, maintaining a Market Outperform rating. This adjustment reflects confidence in Mirum's recently acquired drug zilurgisertib, despite the pivotal PROGRESS trial missing its primary endpoint, due to its convincing overall data and clean safety profile. The firm also considered Mirum's recent $600 million convertible senior notes offering and Wolfe Research's outperform rating for the company, highlighting promising late-stage clinical readouts expected over the next two years.
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte announced positive pivotal Phase 2 results from Cohort 1 of the PROGRESS study for zilurgisertib, an investigational oral ALK2 inhibitor, in adolescents and adults with Fibrodysplasia Ossificans Progressiva (FOP). The study showed meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions, and flare activity. The U.S. FDA has accepted the New Drug Application (NDA) for zilurgisertib in FOP under Priority Review, with a target action date of September 26, 2026.
